RT Journal Article
SR Electronic
T1 Vaccination for some childhood diseases may impact the outcome of covid-19 infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.02.20186528
DO 10.1101/2020.09.02.20186528
A1 Gobe, Irene
A1 Koto, Garesego F
A1 Mokomane, Margaret
A1 Molebatsi, Kesaobaka
A1 Kasvosve, Ishmael
A1 Motswaledi, Modisa S
YR 2020
UL http://medrxiv.org/content/early/2020/09/03/2020.09.02.20186528.abstract
AB Background COVID-19 found the world in a state of unpreparedness. While research efforts to develop a vaccine are on-going, others have suggested the use of available vaccines to boost innate immunity.Objective We analysed three databases: UNICEF Immunization Coverage, Worldometer Corona Virus Updates and World Bank List of Economies to establish the association, if any, between vaccination for various diseases and COVID-19 death rates and recoveries across world economies.Results Mean percentage death rates were lower in countries that vaccinated for Hepatitis-B birth dose (2.53% vs 3.79%, p = 0.001), Bacille Calmette-Guérin Vaccine (2.93% vs 5.10%, p = 0.025) and Inactivated Polio Vaccine 1st dose (2.8% vs 4.01%, p = 0.022) than those which did not report vaccination. In high income countries, a significant negative correlation with death rates was observed with vaccination for Measles-containing vaccine 2nd dose (r = –0.290, p = 0.032), Rubella-containing vaccine 1st dose (r = –0.325, p = 0.015), Hepatitis B 3rd dose (r = –0.562, p = 3.3 x10−5), Inactivated Polio vaccine 1st dose (r = –0.720, p = 0.008). Inactivated Polio Vaccine 1st dose and Measles-containing vaccine 2nd dose also correlated with better recoveries. In Low Income countries, only Rubella-containing vaccine correlated with lower deaths while Yellow fever vaccine was associated with poorer recoveries.Conclusion Our analysis corroborates the potential benefit of vaccination and warrant further research to explore the rationale for repurposing other vaccines to fight COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was necessary for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This was analysis of online data. Therefore no IRB was necessaryAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon request